Latest Ratios: P/E Ratio 35.5x · EV/EBITDA 16.4x · ROE 469.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $74.7B | $64.1B | $74.8B | $66.1B | $66.1B | $72.4B | $73.5B | $59.3B | $52.0B | $67.0B | $58.8B |
| Enterprise Value | $81.4B | $70.8B | $82.2B | $74.2B | $74.6B | $79.4B | $80.8B | $66.9B | $57.6B | $72.0B | $64.0B |
| P/E Ratio → | 35.51 | 30.05 | 25.90 | 28.78 | 36.99 | 33.47 | 27.23 | 25.03 | 21.64 | 33.09 | 24.06 |
| P/S Ratio | 3.67 | 3.14 | 3.72 | 3.40 | 3.68 | 4.16 | 4.46 | 3.78 | 3.34 | 4.33 | 3.87 |
| P/B Ratio | 207.53 | 175.60 | 137.45 | 69.07 | 82.00 | 74.56 | 66.74 | 106.23 | 263.76 | 275.66 | 3458.23 |
| P/FCF | 20.56 | 17.64 | 21.09 | 21.74 | 35.53 | 26.25 | 22.21 | 21.19 | 19.83 | 26.78 | 23.07 |
| P/OCF | 17.80 | 15.27 | 18.21 | 17.65 | 25.86 | 21.77 | 19.76 | 18.92 | 17.00 | 21.93 | 18.72 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.47 | 4.09 | 3.81 | 4.15 | 4.56 | 4.91 | 4.26 | 3.71 | 4.66 | 4.21 |
| EV / EBITDA | 16.36 | 14.22 | 16.48 | 15.79 | 18.06 | 17.87 | 18.16 | 15.62 | 13.21 | 16.06 | 14.54 |
| EV / EBIT | 18.73 | 21.28 | 19.35 | 20.17 | 26.38 | 24.78 | 21.23 | 19.15 | 15.75 | 19.79 | 16.47 |
| EV / FCF | — | 19.48 | 23.18 | 24.41 | 40.10 | 28.79 | 24.42 | 23.90 | 21.99 | 28.80 | 25.12 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.1% | 60.1% | 60.2% | 57.8% | 56.5% | 59.1% | 60.3% | 59.1% | 59.2% | 60.3% | 60.1% |
| Operating Margin | 21.3% | 21.3% | 21.8% | 21.2% | 20.0% | 22.3% | 23.7% | 24.0% | 24.8% | 25.9% | 26.1% |
| Net Profit Margin | 10.5% | 10.5% | 14.4% | 11.8% | 9.9% | 12.4% | 16.4% | 15.1% | 15.4% | 13.1% | 16.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 469.1% | 469.1% | 384.9% | 260.9% | 200.9% | 209.1% | 324.9% | 627.0% | 1090.9% | 1556.9% | 14358.8% |
| ROA | 13.2% | 13.2% | 17.8% | 14.3% | 11.6% | 14.0% | 17.4% | 17.4% | 19.3% | 16.3% | 20.3% |
| ROIC | 43.4% | 43.4% | 38.6% | 33.8% | 31.1% | 35.5% | 35.4% | 40.3% | 51.9% | 57.2% | 55.2% |
| ROCE | 41.6% | 41.6% | 40.0% | 35.3% | 31.6% | 34.5% | 34.7% | 38.0% | 42.6% | 44.3% | 45.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 21.88 | 21.88 | 15.65 | 9.47 | 11.50 | 8.07 | 7.46 | 15.20 | 32.31 | 27.07 | 384.29 |
| Debt / EBITDA | 1.60 | 1.60 | 1.71 | 1.93 | 2.24 | 1.76 | 1.85 | 1.98 | 1.46 | 1.47 | 1.48 |
| Net Debt / Equity | — | 18.36 | 13.63 | 8.46 | 10.54 | 7.21 | 6.65 | 13.62 | 28.63 | 20.75 | 306.94 |
| Net Debt / EBITDA | 1.35 | 1.35 | 1.49 | 1.72 | 2.06 | 1.58 | 1.65 | 1.78 | 1.29 | 1.12 | 1.19 |
| Debt / FCF | — | 1.84 | 2.09 | 2.66 | 4.57 | 2.54 | 2.21 | 2.72 | 2.15 | 2.02 | 2.05 |
| Interest Coverage | 12.46 | 12.46 | 14.55 | 12.82 | 16.93 | 27.38 | 23.79 | 18.19 | 18.95 | 23.79 | 26.09 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.00 | 1.00 | 0.92 | 1.11 | 1.28 | 1.09 | 0.99 | 1.03 | 1.14 | 1.36 | 1.31 |
| Quick Ratio | 0.64 | 0.64 | 0.58 | 0.71 | 0.76 | 0.67 | 0.61 | 0.69 | 0.76 | 1.00 | 0.96 |
| Cash Ratio | 0.22 | 0.22 | 0.22 | 0.20 | 0.19 | 0.21 | 0.20 | 0.22 | 0.22 | 0.45 | 0.40 |
| Asset Turnover | — | 1.25 | 1.25 | 1.19 | 1.14 | 1.16 | 1.03 | 1.04 | 1.28 | 1.22 | 1.25 |
| Inventory Turnover | 4.00 | 4.00 | 4.02 | 4.24 | 3.77 | 4.21 | 3.91 | 4.58 | 5.07 | 5.02 | 5.18 |
| Days Sales Outstanding | — | 30.00 | 27.62 | 29.75 | 30.55 | 27.17 | 28.01 | 33.49 | 32.87 | 34.96 | 33.89 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.4% | 2.8% | 2.4% | 2.6% | 2.6% | 2.3% | 2.0% | 2.7% | 3.1% | 2.3% | 2.6% |
| Payout Ratio | 85.5% | 85.5% | 61.9% | 76.0% | 94.7% | 77.5% | 55.7% | 68.2% | 66.3% | 75.5% | 61.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.8% | 3.3% | 3.9% | 3.5% | 2.7% | 3.0% | 3.7% | 4.0% | 4.6% | 3.0% | 4.2% |
| FCF Yield | 4.9% | 5.7% | 4.7% | 4.6% | 2.8% | 3.8% | 4.5% | 4.7% | 5.0% | 3.7% | 4.3% |
| Buyback Yield | 1.6% | 1.9% | 2.3% | 1.7% | 2.0% | 1.8% | 2.0% | 2.0% | 2.4% | 2.1% | 2.3% |
| Total Shareholder Yield | 4.0% | 4.7% | 4.7% | 4.4% | 4.5% | 4.1% | 4.1% | 4.8% | 5.4% | 4.4% | 4.8% |
| Shares Outstanding | — | $811M | $823M | $829M | $839M | $848M | $859M | $861M | $873M | $888M | $898M |
Emerging market currency volatility
According to current market data, Colgate-Palmolive trades at a trailing P/E of 35.01, which represents a significant premium compared to traditional household peers like Unilever, suggesting that investors are pricing in the therapeutic growth potential of the Hill's Pet Nutrition segment rather than standard consumer staples.
The forward P/E of 24.19 implies that the market expects a meaningful earnings expansion, likely driven by the continued premiumization of the pet food portfolio. Investors should monitor whether this valuation multiple remains sustainable if emerging market currency headwinds continue to dampen reported USD earnings growth.
Based on reported financial figures, Colgate-Palmolive has maintained a consistent ROIC in the 10% to 12% range over the last ten quarters, which, while stable, appears modest relative to the high-margin nature of its professional oral care and veterinary-recommended pet nutrition product lines.
The company's ability to generate these returns is heavily supported by its entrenched brand equity and professional recommendation flywheel. However, the persistent reliance on debt to fund operations suggests that the company's true economic value-add is partially obscured by its highly leveraged capital structure.
As evidenced by the quarterly data, the company's cash conversion cycle has fluctuated between 29 and 51 days, with inventory days outstanding remaining elevated near 90 days, suggesting that the firm carries significant stock to support its global distribution network across diverse and often volatile emerging markets.
The relatively high DIO indicates a potential risk of channel stuffing or the necessity of maintaining deep inventory buffers to mitigate supply chain disruptions. Analysts should watch for any sustained increase in DSO, which could signal weakening customer leverage in price-sensitive regions.
Based on recent SEC filings, the company's debt-to-equity ratio has reached extreme levels, peaking at 21.88 in 2025Q4, a figure that appears alarming in isolation but is largely a function of the company's historically thin book equity base rather than an actual inability to service debt.
The interest coverage ratio, which has remained generally above 15x, provides a more accurate picture of the company's comfortable debt-servicing capacity. Investors should interpret the high D/E ratio as a structural artifact of the company's share repurchase strategy rather than a sign of imminent financial distress.
The Return on Equity (ROE) metric is frequently misapplied to Colgate-Palmolive, as the company's aggressive share buyback program has resulted in a historically compressed equity base, causing the ROE to fluctuate wildly and lose its utility as a reliable measure of operational performance.
Investors should prioritize ROIC or FCF yield over ROE, as these metrics better capture the company's ability to generate returns on its total invested capital. Relying on ROE in this context may lead to an overestimation of management's efficiency or an underestimation of the company's underlying financial stability.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CL stock.
Colgate-Palmolive Company's current P/E ratio is 35.5x. The historical average is 27.5x. This places it at the 83th percentile of its historical range.
Colgate-Palmolive Company's current EV/EBITDA is 16.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.8x.
Colgate-Palmolive Company's return on equity (ROE) is 469.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 148.5%.
Based on historical data, Colgate-Palmolive Company is trading at a P/E of 35.5x. This is at the 83th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Colgate-Palmolive Company's current dividend yield is 2.41% with a payout ratio of 85.5%.
Colgate-Palmolive Company has 60.1% gross margin and 21.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Colgate-Palmolive Company's Debt/EBITDA ratio is 1.6x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.